Lakefront Biotherapeutics NV: all 116 studies

Page 1 of 2. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Long-Term Follow-Up Study of GamgertamigNot yet recruitingNCT07847892
• OM336 in Seropositive Autoimmune DiseasesRecruitingNCT07229144Phase 1
• OM336 in Autoimmune CytopeniasRecruitingNCT07083960Phase 1
• Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell TherapiesRecruitingNCT06652633Phase 3
• A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionTerminatedNCT05479058Phase 3Results posted
• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)TerminatedNCT04700280Phase 2Results posted
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)TerminatedNCT04578548Phase 2Results posted
• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative ColitisCompletedNCT04577794Phase 2Results posted
• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedNCT04577781Phase 2Results posted
• A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic SclerosisTerminatedNCT03976648Phase 2Results posted
• Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedNCT03926195Phase 2Results posted
• A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03864627Phase 2Results posted
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic SclerosisCompletedNCT03798366Phase 2Results posted
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedNCT03733444Phase 3Results posted
• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT03725852Phase 2Results posted
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedNCT03711162Phase 3Results posted
• A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee OsteoarthritisCompletedNCT03595618Phase 2Results posted
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedNCT03201445Phase 2Results posted
• A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic FibrosisCompletedNCT03119649Phase 2Results posted
• Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedNCT02914600Phase 3Results posted
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedNCT02914561Phase 3Results posted
• Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02738801Phase 2Results posted
• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2Results posted
• Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)CompletedNCT01894516Phase 2Results posted
• Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)CompletedNCT01888874Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
• Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsCompletedNCT06043739Phase 1
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT05856448Phase 2
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCompletedNCT05695950Phase 2
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667CompletedNCT05335447Phase 1
• Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsCompletedNCT05272683Phase 1
• Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy SubjectsCompletedNCT05030857Phase 1
• A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04976270Phase 1
• Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsCompletedNCT04971746Phase 1
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970CompletedNCT04907149Phase 1
• A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult SubjectsCompletedNCT04856358Phase 1
• Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsCompletedNCT04736927Phase 1
• Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy SubjectsCompletedNCT04720183Phase 1
• A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970CompletedNCT04708184Phase 1
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205CompletedNCT04704739Phase 1
• A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus ErythematosusTerminatedNCT04700267Phase 1
• A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04653467Phase 1
• A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisCompletedNCT04594928Phase 1
• A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059TerminatedNCT04575818Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male SubjectsCompletedNCT04532567Phase 1
• A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test MedicinesCompletedNCT04137341Phase 1
• A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an InjectionCompletedNCT04136327Phase 1
• A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970CompletedNCT04106297Phase 1
• A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667CompletedNCT04097938Phase 1
• A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male SubjectsCompletedNCT03899909Phase 1
• A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory DiseasesCompletedNCT03800472Phase 1
• A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an InjectionCompletedNCT03787186Phase 1
• A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic DermatitisTerminatedNCT03689829Phase 1
• Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.CompletedNCT03589313Phase 1
• A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic DermatitisTerminatedNCT03568071Phase 2
• A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.CompletedNCT03540524Phase 1
• A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy VolunteersCompletedNCT03515382Phase 1
• GLPG2737 on Top of Orkambi in Subjects With Cystic FibrosisCompletedNCT03474042Phase 2
• Pharmacokinetics of GLPG2737 in Male Subjects With Cystic FibrosisCompletedNCT03450720Phase 1
• A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy SubjectsCompletedNCT03410979Phase 1
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.TerminatedNCT03320876Phase 2
• A Study With GLPG1972 in Osteoarthritis SubjectsCompletedNCT03311009Phase 1
• A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male SubjectsCompletedNCT03214614Phase 1
• Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral SolutionCompletedNCT03143725Phase 1
• Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or TabletCompletedNCT03143712Phase 1
• A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.CompletedNCT03128606Phase 1
• A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing SpondylitisCompletedNCT03117270Phase 2
• This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy SubjectsCompletedNCT03102567Phase 1
• A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
• A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic FibrosisCompletedNCT03045523Phase 2
• Bioavailability Study With GLPG1972CompletedNCT02851485Phase 1
• A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female SubjectsCompletedNCT02788721Phase 1
• First in Human of Single and Multiple Doses of MOR106CompletedNCT02739009Phase 1
• Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)CompletedNCT02707562Phase 2
• Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)CompletedNCT02690519Phase 2
• First-in-Human Single and Multiple Dose of GLPG2222CompletedNCT02662452Phase 1
• A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male SubjectsCompletedNCT02623296Phase 1
• First-in-Human Single and Multiple Dose of GLPG1972CompletedNCT02612246Phase 1
• A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male SubjectsCompletedNCT02562950Phase 1
• Oral Bioavailability of Solid Formulation of GLPG1837 With and Without FoodCompletedNCT02562859Phase 1
• Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative ColitisCompletedNCT02337608Phase 2
• First-in-Human Single and Multiple Dose of GLPG1837CompletedNCT02325037Phase 1
• First-in-Human Single and Multiple Dose of GLPG1690CompletedNCT02179502Phase 1
• Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy SubjectsCompletedNCT02162355Phase 1
• Oral Bioavailability of Solid Formulation of GLPG1205 With and Without FoodCompletedNCT02143856Phase 1
• Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT02084199Phase 1
• Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's DiseaseCompletedNCT02048618Phase 2
• Oral Bioavailability of Two Solid Formulations of GLPG0634CompletedNCT01915667Phase 1
• First-in-Human Single and Multiple Dose of GLPG1205CompletedNCT01887106Phase 1
• Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative ColitisCompletedNCT01829321Phase 2
• Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male SubjectsCompletedNCT01820806Phase 1
• A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy SubjectsCompletedNCT01798979Phase 1
• Multiple Ascending Dose Study of GLPG0974 in Healthy SubjectsCompletedNCT01721980Phase 1
• Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01668641Phase 2
• Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy SubjectsCompletedNCT01665924Phase 1
• Bioavailability Study of Prodrug of GLPG0187 in Healthy VolunteersCompletedNCT01580644Phase 1
• GLPG0492 PharmacodynamicsCompletedNCT01538420Phase 1
• First-in-Human Exploratory Single Ascending Dose of GLPG0974CompletedNCT01496937Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy SubjectsCompletedNCT01419990Phase 1
• Multiple Ascending Dose Study of GLPG0492 in Healthy SubjectsCompletedNCT01397370Phase 1

← Lakefront Biotherapeutics NV overview and focus areas